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Summary
Background: The inability to coordinate the signaling path-
ways that lead to proper cytokine responses characterizes
the pathogenesis of inflammatory diseases such as Crohn’s
disease. The Crohn’s disease susceptibility protein, NOD2,
helps coordinate cytokine responses upon intracellular expo-
sure to bacteria, and this signal coordination by NOD2 is
accomplished, in part, through K63-linked polyubiquitin
chains that create binding surfaces for the scaffolding of
signaling complexes.
Results: In this work, we show that the NOD2 signaling
partner, RIP2, is directly K63-polyubiquitinated by ITCH, an
E3 ubiquitin ligase that when lost genetically causes wide-
spread inflammatory disease at mucosal surfaces. We show
that ITCH is responsible for RIP2 polyubiquitination in response
to infection with listeria monocytogenes. We also show that
NOD2 can bind polyubiquitinated RIP2 and that whereas
ITCH E3 ligase activity is required for optimal NOD2:RIP2-
induced p38 and JNK activation, ITCH inhibits NOD2:RIP2-
induced nuclear factor kappa B (NFkB) activation. This effect
can be seen independently at the whole-genome level by mi-
croarray analysis of muramyl dipeptide (MDP)-treated Itch2/2
primary macrophages.
Conclusions: These findings suggest that ITCH helps regulate
NOD2-dependent signal transduction pathways and, as such,
may be involved in the pathogenesis of NOD2-mediated
inflammatory disease.
Introduction
The Crohn’s Disease susceptibility protein, NOD2, is activated
by intracellular exposure to both gram-positive and gram-
negative bacteria [1–3]. Upon activation, it synergizes with
toll-like receptors (TLRs) [1] to help generate a cytokine
response that is carefully measured for precise delivery of
the correct cytokines, the correct amount of those cytokines,
and the correct duration of release of those cytokines [1–3].
Loss-of-function, Crohn’s Disease-associated NOD2 alleles
lose this ability and cause genetic Crohn’s Disease [1–3],
whereas gain-of-function NOD2 alleles cause the granuloma-
tous disease Blau syndrome and a subset of sporadic early-
*Correspondence: dwa4@case.eduonset sarcoidosis (EOS) cases [4, 5]. The perturbation of
NOD2 signaling in diverse inflammatory diseases suggests
that the coordination of inflammatory signaling pathways by
NOD2 is critical and highly regulated.
Upon activation, NOD2 forms a complex with RIP2 [6–8].
RIP2 is an obligate component for NOD2 signaling; RIP2-
knockout mice cannot generate nuclear factor kappa B
(NFkB), p38, or JNK activation in response to the NOD2 agonist
muramyl dipeptide (MDP, a breakdown product of bacterial
peptidoglycan) [9–11]. Upon activation, the NOD2:RIP2 com-
plex causes lysine-63 (K63) polyubiquitination of lysine-285
on NEMO [7, 8], a component of the NFkB signaling pathway
that is necessary for NFkB activation [12]. Although evolving,
current NOD2:RIP2 signaling models imply that this polyubi-
quitination of NEMO is responsible for binding to the TAK1
complex, allowing TAK1 to phosphorylate and activate I kappa
kinase (IKK), thereby generating an NFkB response [8, 13–16].
Recently, work from independent labs has shown that RIP2 is
also K63-polyubiquitinated in response to the in vitro agonist
MDP and in response to intracellular bacterial infection [14,
15]. This polyubiquitination occurs on lysine-209 (K209) of
RIP2 and is essential for NOD2:RIP2-induced NFkB activation
[15]. Although one study presented data suggesting that
TRAF6 might be mediating RIP2 polyubiquitnation [14], RIP2
polyubiquitination in TRAF6-deficient mouse embryonic fibro-
blasts (MEFs) was similar to that seen in wild-type (WT) MEFs
[15], and although NOD2 activation can cause autoubiquitina-
tion and activation of TRAF6 [8], TRAF6 inhibition by either
dominant-negative constructs or siRNA has no effect on
NFkB activation by the NODs or RIP2 [8, 10]. Given these
disparate findings, the E3 ligase(s) mediating RIP2 polyubiqui-
tination is/are unknown, and the role that these potential E3
ligases play in affecting not just NFkB activation but also p38
and JNK activation downstream of NOD2 activation is
unknown.
Ubiquitination plays a key role not only in the NOD2:RIP2
signaling pathway but also in other innate immune and inflam-
matory pathways. The TLRs, the IL-1 receptor, and the TNF
receptor all required lysine-63 (K63) polyubiquitination of
signaling proteins for optimal cytokine release [16]. Whereas
the more common lysine-48 (K48) polyubiquitin linkage targets
a protein to the proteosome for degradation, K63 polyubiquitin
linkages are thought to serve a scaffolding function for
signaling proteins such that signaling pathways can be acti-
vated and cytokine release achieved [16].
In this work, we find that ITCH (AIP4), a HECT-domain con-
taining E3 ubiquitin ligase [17–21], directly ubiquitinates RIP2
to allow differential NOD2:RIP2 signaling through p38, JNK,
and NFkB. Itch was first identified as the gene underlying the
itchy mouse phenotype [17, 18]. This mouse has a variety of
inflammatory and autoimmune phenotypes [17–20]. Mucosal
surfaces of these mice show varying degrees of inflammation,
and, on a C57BL/6J background, the itchy mice die of pulmo-
nary pneumonitis [17–20]. When itchy mice are crossed into
a Rag1-deficient background, autoimmune-mediated death
no longer occurs [21]. However, mild mucosal inflammation
was present in the itchy animals lacking Rag1, indicating
a putative role for this E3 ligase that is independent of the
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(A) The E3 ligases TRAF2, TRAF3, TRAF4, TRAF6, and ITCH were transfected into HEK293 cells with HA-tagged ubiquitin and NTAP (streptavidin binding
peptide)-tagged RIP2. After cell lysis, streptavidin precipitations were performed under high-stringency washing conditions (1 M NaCl, 1% SDS) to eliminate
potential ubiquitinated RIP2 binding proteins. Immunoblotting was then performed. ITCH expression significantly increased RIP2 ubiquitination.
(B) NTAP-RIP2 was expressed in the presence of HA-ubiquitin and either WT ITCH or catalytically inactive C830A ITCH. The C830A ITCH mutant could not
cause RIP2 ubiquitination.
(C) For determining whether ITCH caused ubiquitination of a previously published RIP2 ubiquitination site (lysine 209–K209), this lysine was mutated conser-
vatively to arginine (K209R). After transfection and high-stringency washing of the streptavidin-agarose precipitate, immunoblotting was performed. ITCH
caused indistinguishable ubiquitination of both WT and K209R RIP2, indicating that ITCH caused ubiquitination of separate site(s) on RIP2.adaptive immune system and is instead important in the innate
immune response [21]. By linking ITCH to the NOD2:RIP2
signaling pathway, this manuscript provides a potential mech-
anism for ITCH’s role in the innate immune system.
Results
For the identification of E3 ligases that can polyubiquitinate
RIP2, a panel of E3 ligases known to be involved in innate
immunity and inflammation were screened for their ability to
induce RIP2 polyubiquitination. TRAF2 (an E3 ligase activated
by TNF [22]), TRAF3 (an E3 ligase activated by innate immune
signals [23, 24]), TRAF4 (an E3 ligase that downregulates TLR
signaling [25]), TRAF6 (an E3 ligase known to be activated by
TLR and NOD signals [14]), and ITCH (a ubiquitously expressed
E3 ligase, which mediates inflammatory signaling and T cell
activation [18–21]) were transfected into 293 cells with HA-
tagged ubiquitin and NTAP (streptavidin binding peptide)-
tagged RIP2. All of the E3 ligases transfected were capable of
autoubiquitination (Figure S1B, available online), suggesting
that they were active in this system. After transfection, lysates
were generated, and RIP2 was purified under stringent
washing conditions (1 M NaCl, 1% SDS) through the use of
streptavidin-agarose beads. Immunoblotting showed that
ITCH expression caused strong RIP2 polyubiquitination and
that none of the TRAFs tested significantly increased RIP2 pol-
yubiquitination (Figure 1A, ubiquitin blot in Figure S1A; note
that all ubiquitin expression blots are shown in the Supple-
mental Data [Figures S1, S3, S4, and S6]). To show that the
RIP2 polyubiquitination was due to ITCH’s E3 ligase activity,
the catalytic cysteine in the HECT domain of ITCH was mutated
to an alanine (C830A ITCH). When this catalytically inactive
ITCH was expressed with RIP2, RIP2 polyubiquitination was
lost (Figure 1B) and another HECT domain containing E3 ligase
(E6AP) did not cause such increased RIP2 ubiquitination
(Figure S2), suggesting that the catalytic activity of ITCH was
necessary for RIP2 polyubiquitination and that this processwas specific to ITCH. To then determine whether ITCH was
the E3 ubiquitin ligase causing K209 ubiquitination, K209 on
RIP2 was conservatively mutated to an arginine (K209R).
Despite this mutation, ITCH-mediated polyubiquitination of
RIP2 was unchanged in comparison to WT RIP2 (Figure 1C).
Additional experiments showed only a small role for TRAF6 in
ITCH-induced RIP2 ubiquitination. ITCH did not appreciably
increase TRAF6 ubiquitination (Figure 2A). NOD2 coexpression
with TRAF6 did not increase RIP2 polyubiquitination (Fig-
ure 2B). Inhibition of TRAF6 expression had a minimal effect
on ITCH-induced RIP2 ubiquitination (Figure 2C), and inhibition
of the E2 mediating TRAF6 activity (Ubc13) did not affect ITCH-
induced RIP2 ubiquitination (Figure 2D). The fact that ITCH
causes ubiquitination of a site distinct from K209 and that the
TRAF6-Ubc13 axis plays a minimal role suggests that the
ITCH mediation of RIP2 ubiquitination site(s) may be causing
distinct signaling effects within the cell.
ITCH-induced RIP2 polyubiquitation could be direct or
could occur through an intermediary E3 ligase. Initial mapping
experiments showed that the CARD domain of RIP2 was
required for ITCH-induced ubiquitination (Figure S3A). We
have found that truncation of the CARD domain is essential
for recombinant RIP2 expression in recombinant systems, so
we utilized 293 cell-expressed, purified full-length NTAP-
RIP2 for in vitro ubiquitination assays. For these assays,
ITCH and the catalytically inactive (C830A ITCH) ITCH mutant
were expressed as GST-fusion proteins in bacteria (Fig-
ure S3B). To determine the optimal E2 for the reaction, we
incubated ITCH with E1, ATP, NTAP-RIP2, and a panel of
E2s in standard in vitro ubiquitination assays. In the presence
of UbcH5, UbcH6, and UbcH7, ITCH could directly ubiquitinate
RIP2 (Figure S3C). After obtaining this information, we per-
formed an in vitro ubiquitination assay to show that there
was not a copurifying bacterial E3 ligase in the recombinant
ITCH preparation. No RIP2 polyubiquitination was identified
in the presence of C830A ITCH (Figure 3A), indicating that
ITCH could directly ubiqutinate RIP2.
Itch Ubiquitinates RIP2 to Affect NOD2 Signaling
1257The lysine linkage on the ubiquitin itself influences the fate of
the polyubiquitinated protein. ITCH has previously been
shown to help synthesize K29-linked [26], K48-linked [19],
and K63-linked [27] polyubiquitin chains. RIP2’s in linkage
was determined in three ways. First, in vitro ubiquitination
assays were performed with the use of recombinant, purified
ubiquitin molecules with specific lysine mutations. In these
mutant ubiquitins, one lysine was mutated to an arginine while
the other lysines remained intact. For instance, K6R ubiquitin
contains a lysine mutated to an arginine at position 6, but all
the other lysines on that mutant are intact. After in vitro
ubiquitination reactions were performed, RIP2 was purified
in high-stringency wash conditions and immunoblotting was
performed. Whereas ubiquitin mutants containing lysines
mutated to arginines at positions 6, 11, 29, and 48 could all
form polyubiquitin chains on RIP2 that were indistinguishable
from WT ubiquitin, K63R ubiquitin could not form these chains
(Figure 3B), indicating that K63-linked polyubiquitin chains are
formed on RIP2 by ITCH in vitro. As a second independent test
for determining the ubiquitin linkage, a ubiquitin construct
containing lysine only at position 48 (K48-only) or one contain-
ing lysine only at position 63 (K63-only) was transfected into
293 cells with NTAP-RIP2 and ITCH. After RIP2 was purified
from the lysate, immunoblotting showed that only the K63-
Figure 2. TRAF6/Ubc13 Has Minimal Involve-
ment in ITCH-Induced RIP2 Ubiquitination
(A) For determining whether ITCH could ubiquiti-
nate TRAF6, RING domain mutant TRAF6 (C70A)
was transfected into 293 cells with ITCH. After
immunoprecipitation in high-stringency buffer,
immunoblotting was performed. Overexposing
the blot revealed very little (if any) effect of ITCH
on TRAF6 ubiquitination.
(B) For determining the strength of TRAF6-
induced ubiquitination of RIP2 relative to ITCH-
induced ubiquitiantion of RIP2, 293 cells were
transfected with the indicated constructs. NOD2
was included, because a prior report had sug-
gested that TRAF6 required NOD2 to ubiquitinate
RIP2 [14]. After precipitation of RIP2 in high-strin-
gency buffer, immunoblotting showed minimal
ubiquitination of RIP2 relative to the cells trans-
fected with ITCH.
(C) For determining whether TRAF6 affected
ITCH-induced RIP2 ubiquitination, TRAF6 ex-
pression was inhibited by two separate siRNAs
[8]. Inhibition of TRAF6 expression caused a small
decrease in ITCH-induced RIP2 ubiquitination;
however, the amount of remaining RIP2 ubiquiti-
nation was still high.
(D) For further determining the effect of TRAF6 on
ITCH-induced RIP2 ubiquitination, the dominant-
negative Ubc13 (C87A) was utilized. Expression
of C87A Ubc13 had minimal effect on ITCH-
induced RIP2 ubiquitination.
only ubiquitin allowed ITCH-mediated
RIP2 polyubiquitination (Figure 3C), indi-
cating again that ITCH induced K63-
linked polyubiquitin-chain formation on
RIP2. As a last independent test of the
ubiquitin linkage, we utilized a deubiqui-
tinase, A20, that recognizes specific pro-
teins with K63-polyubiquitinated chains
and deubiquitinates those proteins [28,
29]. Given that A20 downregulates the
NOD2:RIP2 signaling pathway [29, 30] and has been shown
to deubiquitinate K63-linkages on RIP2 [29], we reasoned
that if RIP2 was K63-polyubiquinated by ITCH, then A20
should recognize the K63-linked chains and remove them.
To this end, A20 was expressed with RIP2 and ITCH. A20
expression caused a significant decrease in the amount of
ITCH-induced polyubiquitinated RIP2 (Figure 3D), further sug-
gesting that ITCH caused K63-linked polyubiquitination of
RIP2. Thus, three separate experimental methods suggest
that ITCH polyubiquitinates RIP2 through K63-specific link-
ages.
Because ITCH-induced K63-linked polyubiquitination of
RIP2 may affect NOD2:RIP2-induced signaling pathways, we
wanted to determine whether RIP2 polyubiquitination affected
NOD2 binding and whether NOD2 could bind to polyubiquiti-
nated RIP2. For this reason, Omni-tagged NOD2 was ex-
pressed with RIP2 with either ITCH or catalytically inactive
C830A ITCH. NOD2 was immunoprecipitated. Immunoblotting
showed that NOD2 could bind to RIP2 in the presence of ITCH
or C830A ITCH. However, when ITCH was present, there was
not only a significant shift in the mobility of total RIP2 (Fig-
ure 4A, second panel from bottom) but also a significant shift
in the mobility of the RIP2 that was bound to NOD2
(Figure 4A, top panel). This shift in the RIP2 bound to NOD2
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pressing catalytically inactive C830A ITCH (Figure 4A, top
panel). To further show that NOD2 can bind to polyubiquiti-
nated RIP2, RIP2 was again expressed with HA-tagged ubiqui-
tin, Omni-tagged NOD2, and a limited amount of ITCH. NOD2
was initially purified via the 6XHis component of the Omni-
tag via nickel beads and then eluted in 200 mM Imidazole.
This NOD2 isolate was then split into two fractions. The first
fraction was subjected to streptavidin-agarose for isolation
of the fraction of RIP2 bound to NOD2. The second fraction
was subjected to anti-HA immunoprecipitation for isolation
of the ubiquitinated proteins present in the NOD2 isolate.
Within the NOD2 isolate, ubiquitinated RIP2 was present, as
shown by the ability of the HA antibody to immunoprecipitate
a significant amount of RIP2 (Figure 4B, second panel from
top, lane 4) and by the ability of the streptavidin-agarose to
precipitate a significant amount of ubiquitinated RIP2 (Fig-
ure 4B, upper panel, lane 3). These findings suggest that
NOD2 can bind to polyubiquitinated RIP2.
We then sought to determine the effect of ITCH on NOD2:
RIP2 signaling pathways. NOD2:RIP2 complex activation
causes not only NFkB activation, but also activation of a
number of signaling pathways, including JNK and p38 [11,
14, 31]. To determine ITCH’s role in NOD2:RIP2 signaling, we
utilized four individual siRNAs to inhibit ITCH’s expression.
Inhibition of ITCH expression by these siRNAs has limited
effect on the activation of JNK, IKKb, or p38 by overexpression
of downstream MAP3Ks (Figures S5A–S5D). Each siRNA tar-
geting ITCH (and a control siRNA) was transfected with RIP2
and with FLAG-JNK (Figure 5A), HA-IKKb (Figure 5B), or
FLAG-p38 (Figure 5C). Immunoprecipitations were then per-
formed for the isolation of JNK, IKKb, or p38. Immunoblotting
Figure 3. ITCH Ubiquitinates RIP2 Directly by
Using K63 Ubiquitin Linkages
(A) NTAP-RIP2 was purified from transfected
HEK293 cells and incubated with recombinant
ITCH, UbcH7, ATP, ubiquitin, and E1 for 60 min
at 37C. RIP2 was then repurified, and immuno-
blots were performed. ITCH could directly ubiqui-
tinate RIP2, and the catalytically inactive C830A
ITCH lost this ability.
(B) In vitro ubiquitination reactions were per-
formed with the use of ubiquitin mutants specifi-
cally mutated at the indicated lysine. RIP2 was
then repurified, and immunoblotting was per-
formed. Only K63R ubiquitin caused a significant
decxrease in RIP2 polyubiquitination.
(C) 293 cells were transfected with RIP2, ITCH,
and either HA-tagged K48-only ubiquitin or HA-
tagged K63-only ubiquitin (all other lysines,
except K48 and K63, respectively, were mutated
to arginine). K63-only ubiquitin caused strong
RIP2 polyubiquitination, whereas K48-only ubiq-
uitin did not.
(D) For further demonstrating this K63 linkage,
the K63 deubiquitinase A20 was transfected
into 293 cells with RIP2, HA-ubiquitin, and/or
ITCH. After precipitation of RIP2, immunoblotting
showed that A20 expression could significantly
impair RIP2 polyubiquitination.
showed that in these cells in which the
individual siRNAs were transfected,
ITCH expression was significantly re-
duced (Figures 5A, 5B, and 5C, bottom
panel). Loss of ITCH expression caused significant decreases
in both JNK (Figure 5A) and p38 (Figure 5C) activity. In
contrast, loss of ITCH expression enhanced RIP2-induced
IKKb activation (Figure 5B). For further independent validation
of this finding, catalytically inactive C830A ITCH was used. In
these conditions, C830A ITCH can act in a dominant-negative
manner ([19], Figure S6A) and has limited effect on activation
of JNK, IKKb, or p38 by overexpression of downstream
MAP3Ks (Figures S6B–S6D). Dominant-negative C830A ITCH
did, however, cause loss of RIP2-induced activation of both
JNK and p38 (Figures S6B and S6C). Consistent with pub-
lished results on the role of ITCH in negatively regulating
TNF-induced NFkB signaling [21], ITCH expression caused
a strong decrease in RIP2-induced IKKb activation, whereas
expression of C830A ITCH not only reversed this inhibition
but also enhanced RIP2-induced IKKb activation (Figure S6B).
Because these experiments utilized overexpression and
in vitro ubiquitination assays, we attempted to determine
whether loss of ITCH expression could affect RIP2 polyubiqui-
tination in more endogenous systems. RIP2 is an essential
component of cellular NFkB and MAP kinase signaling path-
ways initiated by cellular infection by the gram-positive intra-
cellular pathogen, Listeriamonocytogenes [11, 31–33]. Listeria
monocytogenes enters the body by infecting the gastrointes-
tinal epithelium. For this reason, we utilized the gastrointes-
tinal epithelial cell line, HT-29, which expresses NOD2 [34] to
determine whether loss of ITCH expression affected RIP2 pol-
yubiquitination in response to intracellular Listeria infection.
After transfection with the ITCH-targeting siRNAs, HT-29 cells
were infected with Listeria monocytogenes at a multiplicity of
infection (MOI) of 3:1. Endogenous RIP2 was then immunopre-
cipitated. Under these conditions, ITCH expression was
Itch Ubiquitinates RIP2 to Affect NOD2 Signaling
1259Figure 4. NOD2 Binds to Ubiquitinated RIP2
(A) Omni-tagged NOD2 was expressed in 293 cells with RIP2 and either WT ITCH or catalytically inactive C830A ITCH. NOD2 was immunoprecipitated via its
Omni tag, and immunoblots were performed. RIP2 polyubiquitination was enhanced in the presence of ITCH and NOD2 (whole-cell lysate anti-RIP2 panel).
These modified forms of RIP2 were present in the NOD2 immunoprecipitates (upper panel). These modified forms were not seen in the presence of cata-
lytically inactive C830A ITCH; however, binding of RIP2 to NOD2 was unchanged.
(B) Omni-tagged NOD2 was expressed with RIP2, HA-tagged ubiquitin, and ITCH. Ni2+ beads were used for isolating NOD2 via the 6XHis component of the
Omni tag, and NOD2 was then released from the beads by 200 mM Imidazole. This elution was then split into two fractions. One fraction was immunopre-
cipitated with an anti-HA antibody for isolation of ubiquitinated proteins present in NOD2 isolates, and the second fraction was subjected to streptavidin-
agarose pulldowns for isolation of RIP2 from the NOD2 isolate. The HA-ubiquitin immunpreciptates from the NOD2 isolate contained RIP2 (RIP2 blot, lane 4),
and RIP2 precipitates from the NOD2 isolate contained ubiquitinated RIP2 (HA blot, lane 3).significantly inhibited and RIP2 polyubiquitination was attenu-
ated in cells in which ITCH expression was inhibited (Fig-
ure 6A). To determine the signaling effects of listerial infection
of HT-29 s in which ITCH expression was inhibited, HT-29 cells
were infected with listeria under the conditions described
above. Forty-five minutes after extensive washing with PBS
and the subsequent addition of gentamycin to serum-free
media, killing any remaining extracellular bacteria, lysateswere generated, and immunoblotting was performed. Activity
of JNK and p38 was attenuated in cells in which ITCH expres-
sion was inhibited. In contrast, NFkB activity (as shown by total
IkBa and phospho-IkBa) was increased relative to the control
siRNA-transfected cells (Figure 6B). Because listeria monocy-
togenes contains numerous PAMPs that will activate addi-
tional innate immune signaling pathways, a partial response
is not surprising. In all, though, the inhibition of RIP2Figure 5. Inhibition of ITCH Expression Enhances NFkB Signaling and Decreases p38 and JNK Activation
(A) HEK293 cells were transfected with FLAG-JNK (0.5 mg), RIP2 (1 mg), and either a control siRNA or siRNAs targeting ITCH. JNK was purified via its FLAG
tag, and immunoblotting was performed. Decreased ITCH expression strongly inhibited RIP2-induced JNK activation.
(B) HEK293 cells were transfected with HA-IKKb (0.5 mg), RIP2 (0.5 mg), and either a control siRNA or siRNAs targeting ITCH. IKKbwas immunopurified via its
HA tag, and immunoblotting was performed. Decrease in ITCH expression caused increased IKKb activation.
(C) HEK293 cells were transfected with FLAG-p38 (0.5 mg), RIP2 (2.5 mg), and either a control siRNA or siRNAs targeting ITCH. p38 was purified via its FLAG
tag, and immunoblotting was performed. In the presence of RIP2, inhibition of ITCH expression attenuated p38 activity.
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Decreased RIP2 Ubiquitination in Response to
Listeria Infection
(A) HT29 cells were transfected with the siRNAs
targeting ITCH or with a control siRNA. These
cells were then infected with exponentially
growing Listeria monocytogenes at an MOI of
3:1. Endogenous RIP2 was immunoprecipitated
from the lysate, and immunoblotting was per-
formed. RIP2 polyubiquitination was induced by
Listeria infection, but this polyubiquitination
was decreased when ITCH expression was in-
hibited.
(B) HT-29 cells in which ITCH expression was in-
hibited by siRNA transfection were infected with
Listeria. Lysates were generated, and immuno-
blotting was performed. Inhibition of ITCH ex-
pression attenuated p38 and JNK activation but
increased NFkB activity.ubiquitination (Figure 6A), coupled with the signaling re-
sponses seen in Figure 6B, suggests that ITCH affects NOD2:
RIP2 signaling.
For the study of the MDP-induced signaling alterations due
to loss of ITCH expression in a genetic system, age (8-wk-old)-
and sex-matched C57BL/6J WT and itchy mice were sacri-
ficed, and their bone marrow was harvested to obtain bone-
marrow-derived macrophages (BMDMs). After differentiation,
these macrophages were treated with MDP for 60 min. RIP2
was then immunoprecipitated under stringent washing condi-
tions. Immunoblotting showed that RIP2 was ubiquitinated in
these cells upon MDP treatment but that this ubiquitination
was very strongly attenuated in the itchy macrophages (Fig-
ure 7A). Signaling experiments were then performed. Macro-
phages from itchy mice had significantly lower levels of
MDP-induced JNK and p38 activity and significantly higher
levels of NFkB activity (as shown by increased degradation
of IkBa and increased levels of phospho-IkBa [Figure 7B]).
The itchy cells did have increased basal phosphorylation of
IkBa, indicating the possibility of increased basal NFkB activa-
tion. In all, these signaling experiments closely mirror the
results found in both the 293 cell overexpression system and
the HT-29 infection model.
Next, for the determination of whether ITCH was in the NOD2:
RIP2 pathway, WT and Itch2/2 macrophages were either left
untreated or treated with 10 mg/mL for 16 hr. Total RNA was ex-
tracted and microarray analysis was performed. After baseline
gene-expression differences between the WT and Itch2/2
macrophages were subtracted out, whole-genome clustering
analysis showed that WT macrophages could be distinguished
from Itch2/2 macrophages upon MDP treatment (Figure 7C).
This experiment was performed in duplicate, and both results
are shown. The data were then analyzed for the inducible
expression of known NFkB target genes. Itch2/2macrophages
had significantly higher expression of NFkB target genes,
including BCL2, CCL3, IL-1, TNF, ICAM, and TNFAIP2
(Figure 7D). These microarray analyses show that Itch2/2 cells
have a different genetic response to MDP stimulation and that
a number of NFkB target genes are upregulated. These results,
when coupled with the biochemistry/molecular biology of
Figures 1–5, the siRNA results of Figure 6, and the signaling
differences between WT and Itch2/2 macrophages illustratedin Figures 7A and 7B, strongly suggest that ITCH-mediated
RIP2 ubiquitination has functional consequences.
Conclusions
The work presented in this manuscript suggests that ITCH
directly ubiquitinates RIP2 to specify NOD2 signaling re-
sponses. RIP2 has previously been shown by three indepen-
dent groups to be K63-polyubiquitinated [14, 15, 35]. One
group mapped the site of polyubiquitination on RIP2 to
lysine-209 (K209) [15]. This K209 ubiquitination site is required
for NOD2:RIP2-induced NFkB activation [15]. However,
although this group found the ubiquitination to be independent
of TRAF6 [15], another group presented data suggesting that
TRAF6 was the E3 ligase [14]. For this reason, it is unclear
whether K209 ubiquitination is mediated through the TRAF
proteins and the E2 ligase Ubc13 [14, 15]. Our results, like
those of the Nunez and Inohara labs, suggest TRAF6-indepen-
dent ubiquitination machinery for NOD2:RIP2 signaling. Unlike
the TRAF proteins, ITCH-induced RIP2 ubiquitination does not
require Ubc13 (Figure 2D). Inhibition of TRAF6 expression
showed only a small effect on ITCH-induced RIP2 ubiquitina-
tion (Figure 2C), and previous work from our lab [8] and Gabriel
Nunez’s lab [36] showed that although TRAF6 could be acti-
vated by NOD2, neither dominant-negative TRAF6 [36] nor
siRNA inhibition of TRAF6 [8] had any bearing on NOD:RIP2-
induced NFkB activation. Thus, these results, coupled with
the findings in this manuscript, suggest that ITCH-induced
RIP2 ubiquitination is not dependent on TRAF6. Additionally,
a report published while this manuscript was in review also
suggests that RIP2 ubiquitination is independent of TRAF6
[35]. The Saleh group found that the cIAP proteins could
both K48 and K63 ubiquitinate RIP2 and that depending on
the cell type, this ubiquitination was required for p38, JNK,
and/or NFkB signaling [35]. Although our own unpublished
findings indicate that cIAP-1 causes predominantly K48-linked
polyubiquitination of RIP2, given the presence of at least 1000
E3 ubiquitin ligases in the genome, it is not surprising that
multiple E3 ubiquitin ligases can act on a protein to exert
signaling effects. Further work will be required to determine
the interplay between the cIAPs and ITCH in NOD signaling
pathways.
Itch Ubiquitinates RIP2 to Affect NOD2 Signaling
1261ITCH itself plays a role in the immune system. While it is
ubiquitously expressed, mice lacking Itch develop uncon-
trolled inflammatory responses at mucosal surfaces [17, 18,
21]. The lethal aspect of the phenotype is dependent on the
adaptive immune response; itchy mice crossed onto a Rag1-
deficient background show no death due to pulmonary pneu-
monitis. However, the inflammatory phenotype partially
persists in these mice [21], suggesting that ITCH also has
a role in regulating the innate immune response. The work
described here suggests that ITCH may do this by modulating
signaling downstream of NOD2:RIP2 activation. Synthesizing
these data with previously published reports [6–8, 13–15, 30,
36], we hypothesize that upon cellular infection and MDP
exposure, RIP2 dissociates from the protein kinase, MEKK4,
to bind to NOD2. Upon binding to NOD2, a subset of RIP2
becomes ubiquitinated on K209 to stimulate NEMO ubiquitina-
tion and subsequent NFkB activation. Separately, a second
subset of RIP2 is polyubiquitinated by ITCH to activate JNK
and p38 signaling. We hypothesize that ITCH competes with
the K209 E3 ligase to dictate whether JNK and p38 are or
whether NFkB is the predominant downstream pathway after
NOD2:RIP2 activation. It will be important to determine the
ITCH-induced polyubiquitination site on RIP2 and to deter-
mine whether differential polyubiquitination between K209
and the ITCH-mediated site dictates signal specificity down-
stream of NOD2. It will also be important to determine whether
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Figure 7. Loss of ITCH Expression Causes
Increased NFkB-Driven Signaling Responses
(A) BMDMs from 8-wk-old, sex-matched, WT
C57BL/6 or itchy (Itch2/2) C57BL/6 mice were
generated. These cells either were left untreated
or were exposed to MDP (10 mg/mL) for 60 min.
RIP2 was immunoprecipitated, and immunoblot-
ting was performed. MDP-induced RIP2 ubiquiti-
nation was strongly attenuated in the Itch2/2
macrophages.
(B) BMDMs from WT or Itch2/2 mice were treated
with MDP. Lysates were generated, and immuno-
blotting was performed with the indicated anti-
bodies. ITCH2/2 macrophages showed dimin-
ished p38 and JNK activity and increased NFkB
activity.
(C) These BMDMs either were left untreated or
were treated with 10 mg/mL MDP for 16 hr. Total
RNA was harvested, and genomic gene expres-
sion was evaluated by microarray expression
analysis. After subtracting out the basal changes
between the macrophages in the untreated state,
the MDP-treated WT macrophages could be
blindly and bioinformatically distinguished from
the MDP-treated Itch2/2 macrophages.
(D) Analysis of the gene expression differences
between the MDP-treated WT and Itch2/2macro-
phages showed increased expression of NFkB
target genes.
the phenotype of the itchy mice is influ-
enced by the NOD2 signaling pathway
and whether loss of components of the
NOD2 signaling pathway can comple-
ment the inflammatory phenotype seen
in the itchy mice. Lastly, a key question
remains: Where in the cell is NOD2:RIP2
signaling taking place? NOD2 can lo-
calize to the membrane upon exposure
to MDP [37]. MDP uptake by macrophages appears to be
due to an endocytic process involving pannexin-1, and MDP
is ultimately delivered to and possibly escapes from the phag-
olysosome [38]. Because ITCH has been published to localize
to endocytic compartments [19, 26], we suspect that, upon
MDP uptake, the NOD2:RIP2 physiologic interaction with
ITCH localizes to endocytic compartments and that ITCH
helps regulate the initial signaling events after MDP uptake.
In this light, an alternative explanation for the data presented
in the manuscript is that ITCH ubiquitination causes preferen-
tial degradation of RIP2 to decrease NFkB activation. Despite
these questions and the need for future studies, this work
suggests an important regulatory role for ITCH in NOD2:RIP2
signaling pathways and suggests that ITCH may have a role in
the pathophysiology of NOD2-driven inflammatory diseases.
Experimental Procedures
Cell Culture, Immunoprecipitations, and Immunoblotting
HEK293 and HT-29 (ATCC) cells were grown in DMEM containing 5% FBS.
Transfections were performed by calcium phosphate precipitation as previ-
ously described [7]. Immunoprecipitations were performed in 50 mM Tris
(pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 1 mM
b-glycerophosphate, 1 mM PMSF, 1 mM NaVO4, and 10 nM Calyculin A in
the presence of protease inhibitor cocktail (Sigma). After protein G sephar-
ose beads were added, IPs were washed at least five times before immuno-
blotting was performed. For IP-ubiquitination assays, cells were lysed in
Current Biology Vol 19 No 15
1262high-salt modified Cell Signaling Lysis Buffer containing 1 M NaCl and from
0.25% to 1% SDS, as indicated in the text. Immunoblotting was performed
as previously described [7].
Antibodies, Plasmids, and Reagents
Myc (9E10), RIP2, actin, and Omni antibodies were obtained from Santa Cruz
Technology. P4D1 (ubiquitin), Myc (rabbit), phospho IKKa/b, phospho-IkBa,
IKKb, IkBa, NEMO, phospho-JNK, JNK, phospho-p38, and total p38 anti-
bodies were obtained from Cell Signaling Technology. NTAP-RIP2 was
generated by subcloning the Omni-RIP2 construct (EcorI-XhoI) into the
NTAP vector (Stratagene). Omni-RIP2, HA-ubiquitin, Myc-NEMO K399R,
HA-RIP2, Omni-NOD2, FLAG-TAK1, FLAG-p38, HA-MEKK4, FLAG-JNK,
ITCH, C830A ITCH, and HA-IKKb were used as previously described [7, 8,
30, 36]. The K209R RIP2 construct was generated by Quickchange site-
directed mutagenesis (Stratagene).
In Vitro Ubiquitination Assays
ITCH and C830A ITCH were subcloned into pGEX-4T vectors and purified
via standard methodology. For the in vitro ubiquitination assays, E1, the
indicated E2s, WT ubiquitin, and the indicated ubiquitin mutants were all
obtained from Boston Biochem. Reaction mixtures consisted of a buffer
containing 25 mM HEPES (pH 7.4), 100 mM NaCl, 1 mM DTT, 10 mM
MG132, 1 mM ubiquitin aldehyde, 4 mM ATP, 50 ng/mL E1, 1 mg/mL ubiqui-
tin, 200 ng/mL E2, 150 ng/mL ITCH, and NTAP-RIP2 purified from trans-
fected HEK293 cells. Reactions were allowed to proceed at 37C for 1 hr.
The reactions were then diluted in 900 ml of Cell Signaling lysis buffer con-
taining 1 M NaCl and 0.5% SDS, and RIP2 was then immunopurified from
the in vitro reaction.
siRNA
Four separate siRNAs were purchased from QIAGEN. The sequences of
these were as follows: siRNA1, CACGGGCGAGUUUACUAUGUA; siRNA2,
CAAGAGCUAUGAGCAACUGAA; siRNA3, AUGGGUAGCCUCACCAUGAAA;
siRNA4, UGCCGCCGACAAAUACAAAUA. HT-29 cells were transfected with
Dharmafect 4 (Fisher) according to the manufacturer’s protocol.
Listeria Infection
Listeria monocytogenes were grown overnight in BHI media at 37C. The
next morning, the listeria were diluted 1:10 and allowed to grow for another
45 min, such that they were in exponential growth phase. OD600s were per-
formed to quantitate the numbers of listeria and the exponential growth rate
of that listerial culture. Listeria was added to HT-29 cells at a MOI of 3:1.
Forty-five minutes after the addition of listeria to the HT-29 cells, fresh media
containing Gentamycin Sulfate (50 mg/mL final concentration) was added to
kill extracellular bacteria. The infection was then allowed to proceed for
another hour before lysates were generated, protein concentrations were
standardized, and RIP2 was immunoprecipitated. High-stringency washing
and immunoblotting and signaling assays on lysates were performed as
described above.
Microarray Gene Expression Analysis
Total RNA was isolated from WT and Itch2/2macrophages via a QIAGEN kit.
Integrity was analyzed by agarose gel electrophoresis, and RNA quantities
were standardized. Microarray analysis on the RNA was performed by the
Cleveland Clinic Research Institute Core Facility with the use of Illumina
Mouse-6 Bead Chips. Raw Illumina microarray data were quintile normal-
ized, and significant genes (p < 0.05, adjusted for false discovery rate)
were identified with the lumi package in R [39]. Hierarchical clustering and
heatmap analysis of significant genes were performed with Cluster 3.0
and Java TreeView [40].
Supplemental Data
Supplemental Data include seven figures and can be found with this
article online at http://www.cell.com/current-biology/supplemental/S0960-
9822(09)01314-1.
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